Lilly to appeal UK reimbursement denial for Alzheimer's drugs
Eli Lilly says it will appeal the decision after the UK health authorities refused to cover the cost of the Alzheimer’s drug Kisunla through the NHS.
The EU has previously refused to approve Kisunla, pointing out that the efficacy does not outweigh the risk of potentially fatal incidents.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.